Miami Dermatology and Laser Research

Miami, Florida 33173

2 studies enrolling now · 13 studies all time

What they study most

Atopic Dermatitis, Atopic Dermatitis, Unspecified, Chronic Spontaneous Urticaria, Dermatitis, Atopic, Eczema, Eczema, Atopic, Healthy Participants, Plaque Psoriasis, Psoriasis

Studies at this site

• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting now
• FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Recruiting now
• A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color — Completed
• A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection — Stopped early
• A Study of LY3471851 in Participants With Eczema — Completed
• A Study of LY3471851 in Participants With Psoriasis — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis — Stopped early
• A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria — Stopped early